GlucoTrack, Inc. (NASDAQ:GCTK) Short Interest Up 1,933.7% in March

GlucoTrack, Inc. (NASDAQ:GCTK) saw a significant growth in short interest during the month of March. As of March 31st, there was short interest totaling 883,209 shares, a growth of 1,933.7% from the March 15th total of 43,428 shares. Based on an average daily volume of 2,982,970 shares, the short-interest ratio is presently 0.3 days. Currently, 46.5% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of GlucoTrack in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, GlucoTrack currently has an average rating of “Sell”.

Hedge Funds Weigh In On GlucoTrack

Several institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE increased its holdings in shares of GlucoTrack by 102,125.0% in the second quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock valued at $25,000 after purchasing an additional 4,085 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in shares of GlucoTrack in the fourth quarter valued at $52,000. Finally, Ikarian Capital LLC acquired a new position in shares of GlucoTrack in the fourth quarter valued at $177,000. 10.92% of the stock is currently owned by institutional investors and hedge funds.

GlucoTrack Price Performance

NASDAQ:GCTK opened at $0.66 on Friday. GlucoTrack has a one year low of $0.62 and a one year high of $15.90. The company has a market cap of $1.29 million, a P/E ratio of -0.01 and a beta of 0.61. The firm’s fifty day moving average price is $1.31 and its two-hundred day moving average price is $3.98. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.61 and a quick ratio of 1.61.

GlucoTrack (NASDAQ:GCTK) last released its quarterly earnings data on Monday, March 30th. The company reported ($3.98) EPS for the quarter.

About GlucoTrack

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.